MX337115B - Moleculas de union biespecificas que se unen a dll4 y ang2. - Google Patents

Moleculas de union biespecificas que se unen a dll4 y ang2.

Info

Publication number
MX337115B
MX337115B MX2013011032A MX2013011032A MX337115B MX 337115 B MX337115 B MX 337115B MX 2013011032 A MX2013011032 A MX 2013011032A MX 2013011032 A MX2013011032 A MX 2013011032A MX 337115 B MX337115 B MX 337115B
Authority
MX
Mexico
Prior art keywords
dll4
ang2
binding
binding molecules
bispecific
Prior art date
Application number
MX2013011032A
Other languages
English (en)
Other versions
MX2013011032A (es
Inventor
Andreas Gschwind
Joachim Boucneau
Rene Georg Ott
Marie-Ange Buyse
Erik Depla
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44314095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX337115(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2013011032A publication Critical patent/MX2013011032A/es
Publication of MX337115B publication Critical patent/MX337115B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a moléculas de unión biespecíficas que se unen tanto a DII4 como a Ang2, preferiblemente en forma de dominios variables individuales de inmunoglobulina tales como VHH y anticuerpos de dominio, composiciones farmacéuticas que las contienen y su uso en el tratamiento de enfermedades que están asociadas con los efectos mediados por DII4 y/o Ang2 sobre la angiogénesis. Además, también se describen ácidos nucleicos que codifican moléculas de unión biespecíficas, células hospedadoras y métodos para prepararlos.
MX2013011032A 2011-04-01 2012-03-30 Moleculas de union biespecificas que se unen a dll4 y ang2. MX337115B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11160920 2011-04-01
PCT/EP2012/055897 WO2012131076A1 (en) 2011-04-01 2012-03-30 BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2

Publications (2)

Publication Number Publication Date
MX2013011032A MX2013011032A (es) 2013-12-06
MX337115B true MX337115B (es) 2016-02-12

Family

ID=44314095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011032A MX337115B (es) 2011-04-01 2012-03-30 Moleculas de union biespecificas que se unen a dll4 y ang2.

Country Status (23)

Country Link
US (1) US20130078247A1 (es)
EP (1) EP2694545B1 (es)
JP (1) JP2014511682A (es)
KR (1) KR20140016345A (es)
CN (2) CN103596977B (es)
AP (1) AP2013007086A0 (es)
AR (1) AR085919A1 (es)
AU (1) AU2012234218A1 (es)
BR (1) BR112013025294A2 (es)
CA (1) CA2827809A1 (es)
CL (1) CL2013002622A1 (es)
CO (1) CO6801638A2 (es)
EA (1) EA201301109A1 (es)
EC (1) ECSP13012996A (es)
MA (1) MA35233B1 (es)
MX (1) MX337115B (es)
PE (1) PE20141157A1 (es)
PH (1) PH12013502031A1 (es)
SG (1) SG193557A1 (es)
TN (1) TN2013000389A1 (es)
TW (2) TWI535735B (es)
UY (1) UY33997A (es)
WO (1) WO2012131076A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2013144266A1 (en) * 2012-03-30 2013-10-03 Boehringer Ingelheim International Gmbh Ang2-binding molecules
JP2015532273A (ja) * 2012-09-28 2015-11-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ剤を含む薬学的組み合わせ
WO2014049099A1 (en) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
KR102246800B1 (ko) 2014-05-13 2021-04-30 바이오아트라, 인코퍼레이티드 조건부 활성 생체 단백질
CN107540747B (zh) * 2017-08-09 2020-01-24 苏州大学附属儿童医院 抗人dll4单克隆抗体6f12
CN110950967B (zh) * 2019-12-13 2022-05-13 山东民康生物科技有限公司 抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法
CN116444675B (zh) * 2023-05-11 2023-12-22 亲和(武汉)生命科技有限责任公司 一种Pfu DNA聚合酶纳米抗体及其制备方法和应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1621554B2 (en) 1992-08-21 2012-08-29 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP1278544A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
WO2003002609A2 (en) 2001-06-28 2003-01-09 Domantis Limited Dual-specific ligand and its use
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
CA2505326A1 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
EP1578842B1 (en) 2002-12-31 2009-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
ES2315664T3 (es) * 2003-06-30 2009-04-01 Domantis Limited Anticuerpos de dominio unico (dab) pegilados.
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
EP1814917A2 (en) 2004-10-13 2007-08-08 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
ATE537188T1 (de) * 2005-05-18 2011-12-15 Ablynx Nv Serumalbuminbindende proteine
JP5489465B2 (ja) * 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
UA94464C2 (ru) * 2006-06-06 2011-05-10 Дженентек, Инк. Выделенное антитело к dll4 и его применение
EP2029159A2 (en) * 2006-06-06 2009-03-04 Genentech, Inc. Compositions and methods for modulating vascular development
JP2009539384A (ja) * 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 抗ｄｌｌ４抗体および抗ｄｌｌ４抗体使用の方法
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CN101646689A (zh) * 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CN104497143B (zh) * 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CN101965362A (zh) 2008-03-05 2011-02-02 埃博灵克斯股份有限公司 新型抗原结合二聚体-复合物及其制备方法和应用
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
CN102264763B (zh) * 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
UY32917A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2

Also Published As

Publication number Publication date
JP2014511682A (ja) 2014-05-19
CN106046167A (zh) 2016-10-26
TW201302789A (zh) 2013-01-16
EP2694545A1 (en) 2014-02-12
MA35233B1 (fr) 2014-07-03
TWI535735B (zh) 2016-06-01
CO6801638A2 (es) 2013-11-29
TWI551612B (zh) 2016-10-01
ECSP13012996A (es) 2013-12-31
TW201302797A (zh) 2013-01-16
PH12013502031A1 (en) 2013-12-16
CL2013002622A1 (es) 2014-02-14
TN2013000389A1 (en) 2015-01-20
KR20140016345A (ko) 2014-02-07
CN103596977A (zh) 2014-02-19
MX2013011032A (es) 2013-12-06
UY33997A (es) 2012-09-28
SG193557A1 (en) 2013-11-29
EA201301109A1 (ru) 2014-08-29
US20130078247A1 (en) 2013-03-28
BR112013025294A2 (pt) 2017-06-13
AR085919A1 (es) 2013-11-06
WO2012131076A1 (en) 2012-10-04
CN103596977B (zh) 2016-07-06
EP2694545B1 (en) 2016-08-24
AP2013007086A0 (en) 2013-08-31
NZ614243A (en) 2015-04-24
PE20141157A1 (es) 2014-09-24
CA2827809A1 (en) 2012-10-04
AU2012234218A1 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
TN2013000390A1 (en) Bispecific binding molecules binding to vegf and ang2
TN2012000144A1 (en) Dll4-binding molecules
PH12014502179A1 (en) Ang2-binding molecules
TN2013000389A1 (en) BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2
MX2013002379A (es) Moleculas de union a vegf.
MY193112A (en) Anti pd-1 and anti-lag3 antibodies for cancer treatment
WO2014004549A3 (en) Anti-mesothelin binding proteins
TN2012000145A1 (en) Bispecific binding molecules for anti-angiogenesis therapy
PH12019500440A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12014502527A1 (en) St2 antigen binding proteins
MX2012011771A (es) Aptameros para beta-ngf y su uso en el tratamiento de enfermedades y trastornos mediados por beta-ngf.
WO2014031487A8 (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same
MX341578B (es) Tratamiento de la osteoartritis y del dolor.

Legal Events

Date Code Title Description
FG Grant or registration